Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mim8 (NNC0365-3769) prophylaxis in children with haemophilia A
2020-003467-26Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events. Started Sep 2021; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2020-003467-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003467-26.